Form 4: Director Robert Catell Acquires Applied DNA Sciences Stock

Applied DNA Sciences Director Robert Catell acquired 22,511 shares of common stock through a restricted stock unit grant.

Summary

• Robert B. Catell, a Director of Applied DNA Sciences Inc. (BNBX), acquired 22,511 shares of common stock.
• The transaction occurred on October 17, 2025, with a reported acquisition price of $0 per share, indicating a grant.
• These shares are restricted stock units (RSUs) that will vest 100% upon 90 days from the grant date.
• Following this acquisition, Catell's total beneficial ownership stands at 22,512 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even as a grant, generally indicates confidence in the company's future and aligns insider interests with shareholders. No negative information is present in this routine filing.

Positives

• Director Robert B. Catell increased his direct ownership in Applied DNA Sciences Inc. by acquiring 22,511 shares.
• The acquisition of shares by a director, even as a grant, can signal confidence in the company's future prospects and aligns insider interests with shareholders.

Risks

• The value of the acquired shares is subject to market fluctuations of Applied DNA Sciences Inc. common stock.
• The restricted stock units are subject to a vesting period, meaning the director does not have full ownership until 90 days post-grant.

Future Outlook

The filing indicates future vesting of restricted stock units, with 100% vesting 90 days from the grant date of October 17, 2025.

Industry Context

Insider buying, particularly through equity grants to directors, is a common practice designed to align the interests of company leadership with those of shareholders. This type of transaction is generally viewed as a positive signal, suggesting management's belief in the company's future performance.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors as part of their compensation package is a common practice across various industries, aligning director interests with shareholder value.
• The $0 acquisition price is typical for RSU grants, which are a form of equity compensation rather than a market purchase.

Corporate Governance

Related Party Transactions

• Director Robert B. Catell, a related party, received a grant of 22,511 restricted stock units from Applied DNA Sciences Inc. as part of his compensation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value due to direct equity ownership.
• Management: Reinforces commitment from a key board member.

Next Steps

• The restricted stock units are expected to vest 90 days from the grant date of October 17, 2025.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a positive signal of insider alignment but does not provide sufficient new information to warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Applied DNA Sciences, BNBX, Insider Trading, Form 4, Director Stock Acquisition, Restricted Stock Units, Equity Grant